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Summary 
We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced 
tumor necrosis factor ot (TNF<~) production and found that the drug enhances the degradation 
of TNF-oe mRNA. Thus, the half-life of the molecule was reduced from "o30 to ~o17 rain in 
the presence of 50/zg/ml of thalidomide. Inhibition of TNF-ot production was selective, as other 
LPS-induced monocyte cytokines were unaffected. PentoxifyUine and dexamethasone, two other 
inhibitors of TNF-c~ production, are known to exert their effects by means of different mecha- 
nisms, suggesting that the three agents inhibit TNF-c~ synthesis at distinct points of the cytokine 
biosynthetic pathway. These observations provide an explanation for the synergistic effects of 
these drugs. The selective inhibition of TNF-cr production makes thalidomide an ideal candidate 
for the treatment of inflammatory conditions where TNF-c~-induced toxicities are observed and 
where immunity must remain intact. 
T 
halidomide (ot-N-phthalimidoglutarimide) is the drug of 
choice for the treatment of erythema nodosum leprosum 
(ENL), 1 an acute inflammatory complication occurring in 
",,30%  of lepromatous leprosy patients, usually in associa- 
tion with initiation of multidrug therapy (MDT). TNF-c~ 
seems to play a critical role in the pathogenesis of ENL. Serum 
levels of this cytokine have been reported to be elevated during 
ENL episodes, either induced by regular MDT (1), or in a 
combination of MDT and low-dose IFN-~, (1-3).  Therapy 
with thalidomide promptly reduces the toxic symptoms as- 
sociated with ENL, including fever, anorexia, and arthralgia, 
as well as the painful subcutaneous nodules. Thalidomide also 
decreases serum TNF-o~ levels in ENL patients, and inhibits 
the high levels of TNF-ot produced in vitro by monocytes 
obtained from patients during ENL (2). Despite these ob- 
vious antiinflammatory actions of thalidomide, there have been 
no clinical indications that thalidomide reduces any cellular 
or humoral immune reaction in these patients. 
In initial experiments to investigate the relationship be- 
tween thalidomide and TNF-ot, we found that thalidomide 
selectively inhibits the production of TNF-c~ by human mono- 
cytes stimulated in vitro with both LPS and mycobacterial 
products, without influencing the synthesis of other LPS- 
t Abbreviations  used in thislmper: ENL, erythema nodosum leprosum; MDT, 
multidrug  therapy. 
induced monocyte cytokines (3). In the present report, we 
examine the action of thalidomide as well as two other known 
TNF-ot inhibitors. We found that thalidomide inhibits TNF-ot 
production by enhancing the degradation of TNF-ot mRNA. 
By comparison, pentoxifylline, a methylxanthine derivative, 
reduces TNF-ot mRNA accumulation by inhibiting transcrip- 
tion of the TNF-ot gene (4), while the glucocorticoid, dexa- 
methasone, inhibits TNF-c~ production primarily posttran- 
scriptionally by reducing translation (5). Our results provide 
an explanation for the selective  effect of thalidomide on TNF-ot 
production compared with the other monocyte cytokines. 
Materials  and Methods 
Monocyte Isolation.  PBMC from normal donors were obtained 
by Ficoll-Hypaque  (Pharmacia  Fine Chemicals,  Hscataway, NJ) den- 
sity centrifugation. Monocytes were enriched by incubation of 
PBMC with neuraminidase-treated  (Vibrio cholerae neuraminidase; 
Calbiochem-Behring  Corp., La Jolh, CA) sheep  erythrocytes  (Scott 
Laboratories, Friskvikki, RI) for 1 h on ice and separation by cen- 
trifugation over a FicoU-Hypaque  gradient from the rosetted popu- 
lation (E-  cells). CeUs were cultured at 37~  in RPMI  1640 
(Gibco Laboratories, Grand Island, NY) supplemented with 10% 
AB + serum, 100 U/ml penicillin, 100/~g/ml streptomycin, and 
2 mM L-glutamine.  Adherent E- cells (monocytes) were used for 
the studies. 
Cytokine Induction.  LPS of Salmonella minnesota R595 (List Bio- 
logical Laboratories, Campbell, CA) was diluted in PBS, pH 7.4, 
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was determined in previous  experiments to induce optimal TNF-c~ 
protein production by cultured monocytes.  Monocytes  were stimu- 
lated with LPS for 20 h unless otherwise specified. Culture super- 
natants were harvested, centrifuged to remove  cells and debris, and 
kept frozen (- 20~  until TNF-c~ and other cytokine evaluations. 
Cytokine Inhibition.  Thalidomide  (racemic mixture -D[+] and 
L[-] forms; lot no. 1055/8) was donated by Grunenthal, GBMH 
(Stolberg, Germany). Pentoxifylline  and dexamethasone  were pur- 
chased from Sigma Chemical Co. (St. Louis, MO). Drugs were 
diluted in DMSO (Sigma  Chemical Co.) and further dilutions were 
done in sterile RPMI. Final  concentration of DMSO in all assays 
was 0.5%. 
Percentage  inhibition of  cytokine  was calculated  as: 100x [1- (cy- 
tokine experimental/cytokine control)], where cytokine experi- 
mental represents cytokine secretion  by stimulated monocytes that 
were cultured in the presence of thalidomide and 0.5% DMSO, 
and cytokine control represents cytokine secretion by stimulated 
monocytes that were cultured in 0.5% DMSO in the absence of 
the drug. Monocytes cultured in medium containing equivalent 
amounts of DMSO in the presence or absence of the stimulating 
agent were used as controls. Neither thalidomide nor DMSO had 
any effect on cell viability or function at the concentrations used 
(not shown). 
Cytokine Determination.  Commercial ELISA  kits were used ac- 
cording to the manufacturer's  specifications  to determine  the amount 
of TNF-ot, GM-CSF (Endogen Inc., Boston, MA), I1.-6 (Genzyme 
Corp., Cambridge, MA), and II.,1B (Cistron, Pine Brook, NJ) pro- 
teins in culture medium. Cytokine levels are expressed as picograms 
per milliliter. 
Northern Blot Hybridization.  Total  cellular RNA from stimu- 
lated monocytes was isolated using the  guanidine thiocyanate- 
phenol-chloroform  method and quantified  by absorbance at 260 nm. 
RNA was size fractionated  by formaldehyde/agarose  gel electropho- 
resis and transferred to nylon membranes (Bio-Rad Laboratories, 
Richmond, CA) in the presence of 10x  SSC (lx  SSC is 0.15 M 
NaCI, 15 mM sodium citrate). The membranes were crosslinked 
by UV radiation  and then treated  overnight  at 42~  with prehybridi- 
zation solution (50% formamide, 5.x  SSC, 5 x  Denhardt's solu- 
tion, 0.02 M NaHPO4, pH 6.5, 100/~g/ml of heat-denatured 
sheared salmon sperm DNA, and 10% dextran sulfate). This solu- 
tion was then replaced with one containing l& cpm/ml of heat- 
denatured 32P-labeled cDNA random-primed (U.S. Biochemical 
Corp., Cleveland, OH) probe for II.,1/~ (0.6-kB BamHI  +  SmaI 
fragment; American Type Culture Collection, Rockville, MD), 
TNF-c~ (1.3-kB PstI fragment; gift of  Dr. A. Cerami), and ~-actin 
(1.2-kB EcoRI-XhoI fragment) (6). The filters were hybridized at 
42~  overnight. The membranes were washed twice for 15 min 
at room temperature with 2x SSC and 0.1% SDS, 30 min at room 
temperature with 0.1x  SSC and 0.1% SDS, and 30 min at 60~ 
with 0.1x  SSC and 0.1% SDS. After air drying, the blots were 
exposed to x-ray film for 12-24 h at  -70~  and developed in a 
Kodak X-Omat processor stand. Densitometry  was performed  using 
a phosphorimager (Molecular  Dynamics, Inc., Sunnyvale,  CA), and 
results are expressed as density units. 
mRNA Degradation Assay.  Monocytes were stimulated with 
LPS (1 /~g/ml) for 2 h. Cells were washed twice in RPMI and 
further incubated in medium supplemented with actinomycin-D 
(5 /~g/ml) (Calbiochem-Behring Corp.). After 30-60 rain, cells 
were washed and lysed for RNA extraction.  Thalidomide (50 
/~g/ml), pentoxifylline  (30/zg/ml), and dexamethasone  (100 nM/ml) 
were added together with actinomycin-n-supplemented  medium. 
The degradation of  TNF-c~ mRNA in the drug-treated groups was 
compared with RNA from cells treated only with actinomycin-D. 
In some experiments LPS-stimulated monocytes were cultured in 
the presence of cycloheximide  (10 ttg/ml) (Sigma Chemical Co.) 
or cycloheximide  plus actinomycin-n for 1 h and then processed 
for RNA extraction. The decay of TNF-ot mRNA was analyzed 
by Northern blot hybridization and quantitated as described above. 
Results 
Comparison of the Effect of Thalidomide, Pentoxifylline, and 
Dexamethasone on Monocyte Cytokine Production.  Although 
pentoxifylline and dexarnethasone are  known to  decrease 
TNF-ot production, their effects on other monoc3rte cytokines 
have not been explored in detail. Therefore, thalidomide was 
first compared with these agents for suppressive  effects on 
the secretion of several cytokines, including I1-1~,  I1-6, and 
GM-CSF,  in addition to TNF-ot.  As reported previously, 
thalidomide inhibited TNF-ot release from LPS-stimulated 
monocytes in  a concentration-dependent fashion without 
influencing the production of ILI~ and II-6. GM-CSF ap- 
peared not to consistently be inhibited (Fig. 1). By compar- 
ison, pentoxifylline inhibited TNF-ot and GM-CSF produc- 
tion, but had no effect on II-18 or I1-6 release. Dexamethasone 
was broadly suppressive, inhibiting the production of all four 
cytokines tested. 
Given that the three agents displayed different patterns of 
inhibition of monocyte cytokines, suggesting possible differ- 
ences in mechanism, we next tested them for synergism of 
TNF-ot suppression. Concentrations of pentoxifyUine and dex- 
amethasone that resulted in ~25%  inhibition (ICzs) were 
combined with varying concentrations of thalidomide. As 
shown in Fig. 2, the combination of thalidomide with pen- 
toxifylline or dexamethasone resulted in synergistic inhibi- 
tion of TNF-c~ production in both instances. 
TNF-ce mRNA Expression.  In initial experiments thalido- 
mide was found to suppress TNF-c~ mRNA expression, when 
assayed 6 h after stimulation with LPS. Since pentoxifylline 
was reported to inhibit TNF-ot transcription, additional ex- 
periments were performed, comparing thalidomide and pen- 
toxifylline. As shown in Fig. 3, thalidomide and pentoxifyl- 
line  yielded  comparable  inhibition  of  TNF-ot  mRNA 
expression measured 6 h after LPS stimulation. As already 
reported by Han et al.  (5),  dexamethasone does not affect 
mRNA level for TNF-ot. 
Previous reports indicated that TNF-c~ mRNA expression 
peaks within 3 h of stimulation and declines thereafter (7). 
Therefore, a kinetic study of thalidomide inhibition of TNF-ot 
mRNA levels was performed as shown in Fig. 4. There was 
little, if any, inhibition of mRNA expression  at 3 h, but at 
later time intervals the suppressive effect of thalidomide be- 
came apparent. When the amount of mRNA present after 
12  h  of LPS stimulation was compared with the secreted 
TNF-cr protein, the results were remarkably similar: thalido- 
mide suppressed  mtLNA by 50% (Fig. 4) and TNF-ot pro- 
tein by 43%  (not shown). 
The Effect of Thalidomide on TNF-ot mRNA  Degradation. 
The lack of a discernible effect of thalidomide on TNF-c~ 
mRNA expression  at early time intervals after LPS stimula- 
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Figure  1.  Effect  of thalidomide, pentoxifyUine, and 
dexamethasone on LPS-induced cytokine production 
by human monocytes.  Monocytes  were stimulated with 
LPS (1 #g/m1) for 20 h. Drugs were added to the cells 
at the same time as the agonist. Cytokine release into 
the supematant was assayed  by ELISA.  (Tha/) thalido- 
mide;  (Pent) pentoxifylline;  (Dex)  dexamethasone. 
tion, but dear effects at later time intervals, pointed towards 
a posttranscription level of control.  Therefore, the effect of 
thalidomide on TNF-ol mKNA stability was examined and 
compared with that of pentoxifylline and dexamethasone. As 
shown in Fig. 5, thalidomide accelerated the degradation of 
TNF-ol  mRNA  twofold,  such  that  the  half-life  (t~)  de- 
creased from 30 to 17 min. In contrast, pentoxifylline  and 
dexamethasone had no effect on TNF-c~ mKNA  stability. 
Degradation  of TNF-c~ mKNA in LPS-stimulated mono- 
cytes was also evaluated in the presence of cycloheximide,  a 
protein  synthesis  inhibitor.  A  superinduction  of TNF-c~ 
mKNA was observed (8-10). In the presence of cydohexi- 
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Figure 2.  Synergistic effects ofdexamethasone and pentoxifylline with 
thalidomide on TNF-cx production.  Monocytes were cultured with LPS 
(1 #g/ml) and different concentrations  of thalidomide with or without 
pentoxif-ylline  or dexamethasone added at suboptimal doses (IC2s). Cyto- 
kine released  in the supernatant was measured  after 20 h of  culture by ELISA. 
mide and thalidomide, there was less TNF-o~ mRNA, when 
compared with cycloheximide alone (not shown). When both 
cycloheximide and actinomycin-D were added to the cells, the 
presence of thalidomide still accelerated the decay of TNF-o~ 
mRNA, suggesting that thalidomide requires  neither new 
mRNA synthesis nor protein synthesis to reduce TNF-cz levels 
(Fig.  6). 
Figure 3.  Effect  of thalidomide and pentoxifylline on TNF-oL  mRNA 
expression in monocytes stimulated  with 1/~g/ml LPS as analyzed by 
Northern blot hybridization.  Cells were incubated with LPS for 6 h in 
the presence of 20 or 50/tg/ml of thalidomide or pentoxif'ylline.  Gels were 
loaded with 20/~g RNA per lane. (Tbp) Densitometric  analysis of the 
x-ray shown. The optical density for TNF-cx was normalized to the op- 
tical density for ~-actin (on the same blot) for each lane (OD ratio). Results 
are expressed as percent  of maximum density  obtained  with the LPS- 
stimulated cells. (Bottom) Autoradiography of the Northern blot exposed 
for optimal photography  for both mRNAs on the same blot. 
Discussion 
The resuhs of these experiments indicate that thalidomide 
suppresses TNF-cz production primarily by accelerating  the 
degradation of TNF-~x mKNA transcripts. Compared with 
two other known inhibitors of TNF-c~ production, the glu- 
cocorticoid dexamethasone and the methylxanthine deriva- 
tive pentoxifylline, thalidomide is unique in its mechanism 
of action and its selectivity. Thus, our data suggest that the 
three TNF-ol inhibitors affect TNF-cx synthesis at distinct 
points of the cytokine biosynthesis pathways,  providing a 
strong rationale for synergistic use of the drugs in patients. 
For these experiments bacterial LPS was used as the agonist 
to promote monocyte TNF-c~ production. After stimulation 
by LPS, a marked increase in TNF-cx gene transcription occurs, 
resulting in a rapid accumulation of mRNA (7). However, 
TNF-ot production is also regulated at the level of mRNA, 
in that the transcripts  are very short-lived,  with a t,a of only 
30 min (7). In addition, TNF-ot translation has also been 
shown to be promoted by LPS stimulation, primarily by 
derepression of translational control (11). By accelerating the 
decay of TNF-ot transcripts, thalidomide appears to have a 
marked regulatory influence on the total amount of TNF-ol 
Figure 4.  Effect  of thalidomide on mRNA cytokine expression from 
monocytes stimulated with 1/~g/ml LPS as analyzed by Northern blot 
hybridization. PBMC from one huffy coat were incubated with endotoxin 
for 3, 6, or 12 h (lanes 1-7) or PBMC from another buffy coat for 6 or 
12 h (lanes 8-12) in the absence or presence of 20 #g/ml of thalidomide 
(lane 4, 6, and 9) or isomers: D(+) (lanes 7 and 11) or L(-) (lane 12). 
Gels were loaded with 15/~g/ml RNA per lane. Autoradiographs were 
exposed for 48 h (top) or for 8 b (middle) for TNF-cx, or for I h for IL-1/~ 
(bottom) for optimal photographic results. All exposures were carried out 
on the same blot. 
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Figure  5.  Effect of thalidomide  on TNF-ot mRNA degradation.  Cells 
were stimulated  with LPS for 2 h when actinomycin-D and thalidomide 
(50/zg/ml) were added to the culture.  RNA extraction  was performed 
30 and 60 rain after the addition  of actinomycin-D. The decay of TNF-ot 
mRNA was analyzed by Northern blot hybridization.  The results are ex- 
pressed as percentage  of density units of TNF-n, normalized  to B-actin 
for each lane evaluated by phosphorimaging exposed for 18 h for both 
mRNAs on the same blot. Cells were cultured with actinomycin-D only 
(O) or with actinomycin-D and thalidomide  (0), pentoxifylline  (&), or 
dexamethasone  (,).  Results  for actinomycin-D only and actinomycin-D 
and thalidomide are means -e SD of four and two experiments, respectively. 
protein eventually released in response to LPS stimulation. 
The lack of an early effect of thalidomide on mRNA and 
the prominence of the effect later is consistent with an effect 
on mRNA degradation rather than on transcription. 
The selective  inhibition of  TNF-cz, but not other cytokines, 
depends on different regulatory pathways for the different 
monocyte cytokines tested. The mechanisms by which LPS 
promotes the production of the other cytokines have been 
shown to differ from that of TNF-cr  in minor but appar- 
ently important ways. For example, LPS stimulates Ibl gene 
transcription but has no detectable effect on mRNA stability 
or rate of translation  of ILl mRNA (12). By comparison, 
LPS promotes GM-CSF production by stabilizing the labile 
GM-CSF mRNA transcripts (13). Our results indicate that 
mRNA degradation of the other cytokines is also regulated 
differently from that of TNF-cr  and therefore not affected 
by thalidomide.  Selective mRNA degradation  or stabiliza- 
tion has been shown to be an important way for the cell to 
retain or downregulate the activity of a gene (14-16). Lind- 
stein et al. (17) described that stimulation of the T cell by 
CD28 surface  molecule leads specifically  to stability ofmRNA 
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Figure  6.  Effect of thalidomide  on TNF-ot mRNA in cycloheximide 
and actinomycin-D-treated cells. Cells were stimulated with LPS (1/zg/ml) 
for 2 h. Cycloheximide  (10 tzg/ml) was then added to the cultures  and 
the cells were cultured for an additional 1 h, when actinomycin-D (5 #g/ml) 
with or without thalidomide  (50/zg/ml) was added. RNA was allowed 
to decay for another 1 h, extracted,  and analyzed for Northern blot hy- 
bridization. The results are expressed as percentage of  density units of TNF-o~ 
normalized  to/~-actin for each lane, evaluated by phosphorimaging ex- 
posed for 18 h for both mRNAs on the same blot. Results  are means 
_+  SD for two experiments. 
for II.-2, IFN-7, TNF-ol, and GM-CSF, while mRNA half- 
life for c-myc, c-~s,  and IL2 receptor is not affected. 
The selective  inhibition of TNF-cr in the absence  of  general 
inhibition of other monocyte cytokines makes thalidomide 
an ideal candidate for the treatment of inflammatory condi- 
tions where immunity must remain intact. This selective in- 
hibition of TNF-ot does not mean that the drug does not 
impact on other inflammatory cytokines.  Since TNF-cz is 
known to modulate synthesis of other cytokines and other 
inflammatory  molecules (18), the inhibition of TNF-cz could 
ultimately lead to a reduction in other inflammatory medi- 
ators, including 1I.-1/3, IL-6, I1,8, and GM-CSF. Thus, thalido- 
mide could be used in acute infections such as meningitis 
or chronic infections such as tuberculosis, AIDS, and para- 
sitic disease in order to overcome the toxic manifestations 
of TNF-ot without compromising the host's cellular immune 
response. Since pentoxifylline inhibits TNF-cz production by 
suppressing transcription, one would anticipate that it would 
synergize with thalidomide, as well as synergizing with dexa- 
methasone.  Pentoxifylline is not immunosuppressive,  sug- 
gesting that long-term treatment of patients with the com- 
bination of thalidomide and pentoxifylline may be better than 
long-term use of dexamethasone. This is especially true in 
diseases such tuberculosis and AIDS, where an intact cellular 
1679  Moreira  et al. immune response is crucial for disease control. Our results 
also suggest that a reduction in TNF-o~ production can be 
achieved by both isomers of thalidomide. It is not clear  at 
this time whether racemization occurs between the two enan- 
tiomeres. However, if racemization does not occur, this ob- 
servation is specially important since the optical D(+) form 
of this drug has been reported not to be teratogenic (19). 
We thank Judy Adams for help with the graphics and Susanne Dennehy for skillful technical help. 
These studies were supported in part by U.S. Public Health Service grants AI-22616 and AI-33124, and 
by Celgene Corporation.  A. L. Moreira and E. P. Sampaio are Villares Fellows. 
Address correspondence  to Gilla Kaplan, Laboratory of  CeUular Physiology  and Immunology, The Rocke- 
feller University, 1230 York Avenue, New York, NY 10021. E. P. Sampaio's present address is Oswaldo 
Cruz Foundation, Leprosy Unit, AV. Brasil 4365, Manguinhos, Rio de Janeiro, RJ. Brazil, 21045. 
Received for publication 12 January  1993 and in revised form  10 March 1993. 
References 
1.  Sarno, E.N., G.E. Gran, L.M.M. Vieira, and A.C. Nery. 1991. 
Serum levels of TNF-c~ and IL-I~ during leprosy reactional 
states. Clin. Exl~ Immunol. 84:103. 
2.  Sampaio, E.P., A.L. Moreira, E.N. Sarno, A.M. Malta, and 
G. Kaplan. 1992. Prolonged treatment with recombinant in- 
terferon ~/induces erythema nodosum leprosum in leproma- 
tous leprosy patients. J. Extx Med. 175:1729. 
3.  Sampaio, E.P., E.N.  Sarno, R. GaliUy, Z.A. Cohn, and G. 
Kaplan. 1991. Thalidomide selectively  inhibits tumor necrosis 
factor c~ production by stimulated human monocytes.  J. Exp. 
Med. 173:699. 
4.  Doherty, G.M., J.C. Jensen, H.R. Alexander, C.M. Buresh, 
and J.A. Norton. 1991. Pentoxifylline suppression of tumor 
necrosis factor gene transcription. Surgery (St. Louis). 110:192. 
5.  Han, J., P. Thompson, and B. Beutler. 1990. Dexamethasone 
and Pentoxifylline  inhibit endotoxin induced cachectin/tumor 
necrosis factor synthesis at separate points in the signaling 
pathway. J. Extx Med. 172:391. 
6.  Gunning, P., Ponte, H. Okayama, J. Engles, H. Blau, and L. 
Kedes. 1983. Isolation  and characterization  of  fuU-length  cDNA 
clones for human a-fl and 3'" actin mRNAs: Skeletal  but not 
cytoplasmic actins have an amino-terminal cystein that is sub- 
sequently removed. Mol. Cell. Biol. 3:787. 
7.  Beutler, B., and A. Cerami. 1988. The common mediator of 
shock, cachexia, and tumor necrosis. Adv. Immunol. 42:213. 
8.  Sen, R., and D. Baltimore. 1986. Inducibility of K  immuno- 
globulin enhancer-binding  protein NF-KB  by a posttranslational 
mechanism. Cell. 47:921. 
9.  Sariban,  E., K. Imamura, R. Luelbers,  and D. Kufe. 1988. Tran- 
scriptional and posttranscriptional  regulation of tumor necrosis 
factor gene expression in human monocytes. J. Clin. Invest. 
81:1506. 
10.  Zuckerman, S.H., G.F. Evans, and L. Guthrie. 1991. transcrip- 
tional and post-transcriptional mechanisms involved in the 
differential  expression of LPS-induced Ibl and TNF mRNA. 
Immunology 73:460. 
11.  Han, J., T. Brown, and B. Beutler. 1990. Endotoxin-responsive 
sequences control cachectin/tumor necrosis factor biosynthesis 
at the translational level.  J. Exp. Med. 171:465. 
12.  Sung,  S.S., andJ.A. Waiters. 1991. Increased  cyclic  AMP levels 
enhance IL-1 alpha and IL-1 beta mRNA expression and pro- 
tein production in human myelomonocytic  cell  lines  and mono- 
cytes. J. Clin. Invest. 88:1915. 
13.  Thorens, B., J.J. Mermod, and P. Vassali. 1987. Phagocytosis 
and inflammatory stimuli induce GM-CSF mRNA in macro- 
phages through posttranscriptional regulation. Cell. 48:671. 
14.  Shaw, G., and R. Kamen. 1986. A conserved AU sequence 
from the 3' untranslated region of GM-CSF mRNA mediates 
selective mRNA degradation. Cell. 46:659. 
15.  Beulter, B., N. Krochin, I.W. Mitsark, C. Luedke, and A. 
Cerami. 1986. Control of cachectin (tumor  necrosis factor) 
synthesis: Mechanisms of endotoxin resistance. Science (Wash. 
DC). 232:977. 
16.  Han, J., G. Huez, and B. Beutler. 1990. Interactive effects of 
the tumor necrosis factor promoter and Y-untranslated region. 
j. Immunol. 146:1843. 
17. Lindstein, T., C.H. June, J.A. Ledbetter, G. Stella, and C.B. 
Thompson. 1989. Regulation of  lymphokine messenger  R.NA 
stability  by a surface-mediated  T cell activation  pathway.  Science 
(Wash. DC).  244:339. 
18.  Fong, Y., K.J. Tracey, and L.L. Maldawer et al. 1989. Anti- 
bodies to cachectin/tumor  necrosis factor reduce interleukin 
18 and interleukin 6 appearance during lethal bacteremia. J. 
Extx Med. 170:1627. 
19.  Blaschke,  G. 1986. Chromatographic resolution ofchiral drugs 
on polyamides  and cellulose  triacetate.J. Liq. Chromatogr. 9:341. 
1680  Thalidomide  Inhibits TNF-ot by Enhancing mRNA Degradation 